Philip J O'Halloran1,2, Thomas Viel3,4, David W Murray1, Lydia Wachsmuth5, Katrin Schwegmann3, Stefan Wagner6, Klaus Kopka6,7, Monika A Jarzabek1, Patrick Dicker8, Sven Hermann3, Cornelius Faber5, Tim Klasen5, Michael Schäfers3,6, David O'Brien2, Jochen H M Prehn1, Andreas H Jacobs3,9,10, Annette T Byrne11. 1. Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin 2, Ireland. 2. National Neurosurgical Department, Beaumont Hospital, Dublin 9, Ireland. 3. European Institute for Molecular Imaging (EIMI), Westfälische Wilhelms-Universität (WWU) Münster, Münster, Germany. 4. PARCC, INSERM U970, Université Paris Descartes, Paris, France. 5. Department of Clinical Radiology, University Hospital Münster, Münster, Germany. 6. Department of Nuclear Medicine, Münster University Hospital, Münster, Germany. 7. Radiopharmaceutical Chemistry, German Cancer Research Centre (dkfz), Heidelberg, Germany. 8. Department of Epidemiology & Public Health, Royal College of Surgeons, Dublin 2, Ireland. 9. Interdisciplinary Centre of Clinical Research (IZKF), Westfälische Wilhelms-Universität (WWU) Münster, Münster, Germany. 10. Department of Geriatric Medicine, Johanniter Krankenhaus, Bonn, Germany. 11. Department of Physiology and Medical Physics, Royal College of Surgeons in Ireland, Dublin 2, Ireland. annettebyrne@rcsi.ie.
Abstract
PURPOSE: Resistance to bevacizumab (BEV) in glioblastoma is believed to occur via activation of molecular networks including the mTOR/PI3K pathway. Using an MR/PET molecular imaging biomarker approach, we investigated the response to combining BEV with the mTOR/PI3K inhibitor BEZ235. METHODS: Tumours were established by orthotopically implanting U87MG-luc2 cells in mice. Animals were treated with BEZ235 and/or BEV, and imaged using diffusion-weighted-MRI, T2-weighted and T2*-weighted before and after administration of superparamagnetic iron oxide contrast agent. Maps for changes in relaxation rates (ΔR2, ΔR2* and apparent diffusion coefficient) were calculated. Vessel size index and microvessel density index were derived. 3'-Deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) PET and O-(2-[(18)F]fluoroethyl)-L-tyrosine ([(18)F]FET) PET were further performed and tumour endothelium/proliferation markers assessed by immunohistochemistry. RESULTS: Treatment with BEV resulted in a pronounced decrease in tumour volume (T2-weighted MRI). No additive effect on tumour volume was observed with the BEV/BEZ235 combination compared with BEV monotherapy. The Ki67 proliferation index and [(18)F]FLT uptake studies were used to support the observations. Using ΔR2* and ΔR2 values, respectively, the BEV/BEZ235 combination significantly reduced tumour microvessel volume in comparison to BEV alone. Decreased microvessel density index was further observed in animals treated with the combination, supported by von Willebrand factor (vWF) immunohistochemistry. [(18)F]FET uptake was decreased following treatment with BEV alone, but was not further reduced following treatment with the combination. vWF immunohistochemistry analysis showed that the mean tumour vessel size was increased in all cohorts. CONCLUSION: Assessing MR imaging biomarker parameters together with [(18)F]FET and [(18)F]FLT PET provided information on mechanism of action of the drug combination and clues as to potential clinical responses. Following translation to clinical use, treatment with a BEV/BEZ235 combination could reduce peritumoral oedema obviating the requirement for steroids. The use of hypothesis-driven molecular imaging studies facilitates the preclinical evaluation of drug response. Studies of this kind may more accurately predict the clinical potential of the BEV/BEZ235 combination regimen as a novel therapeutic approach in oncology.
PURPOSE: Resistance to bevacizumab (BEV) in glioblastoma is believed to occur via activation of molecular networks including the mTOR/PI3K pathway. Using an MR/PET molecular imaging biomarker approach, we investigated the response to combining BEV with the mTOR/PI3K inhibitor BEZ235. METHODS: Tumours were established by orthotopically implanting U87MG-luc2 cells in mice. Animals were treated with BEZ235 and/or BEV, and imaged using diffusion-weighted-MRI, T2-weighted and T2*-weighted before and after administration of superparamagnetic iron oxide contrast agent. Maps for changes in relaxation rates (ΔR2, ΔR2* and apparent diffusion coefficient) were calculated. Vessel size index and microvessel density index were derived. 3'-Deoxy-3'-[(18)F]fluorothymidine ([(18)F]FLT) PET and O-(2-[(18)F]fluoroethyl)-L-tyrosine ([(18)F]FET) PET were further performed and tumour endothelium/proliferation markers assessed by immunohistochemistry. RESULTS: Treatment with BEV resulted in a pronounced decrease in tumour volume (T2-weighted MRI). No additive effect on tumour volume was observed with the BEV/BEZ235 combination compared with BEV monotherapy. The Ki67 proliferation index and [(18)F]FLT uptake studies were used to support the observations. Using ΔR2* and ΔR2 values, respectively, the BEV/BEZ235 combination significantly reduced tumour microvessel volume in comparison to BEV alone. Decreased microvessel density index was further observed in animals treated with the combination, supported by von Willebrand factor (vWF) immunohistochemistry. [(18)F]FET uptake was decreased following treatment with BEV alone, but was not further reduced following treatment with the combination. vWF immunohistochemistry analysis showed that the mean tumour vessel size was increased in all cohorts. CONCLUSION: Assessing MR imaging biomarker parameters together with [(18)F]FET and [(18)F]FLT PET provided information on mechanism of action of the drug combination and clues as to potential clinical responses. Following translation to clinical use, treatment with a BEV/BEZ235 combination could reduce peritumoral oedema obviating the requirement for steroids. The use of hypothesis-driven molecular imaging studies facilitates the preclinical evaluation of drug response. Studies of this kind may more accurately predict the clinical potential of the BEV/BEZ235 combination regimen as a novel therapeutic approach in oncology.
Authors: Klaus P Schäfers; Andrew J Reader; Michael Kriens; Christof Knoess; Otmar Schober; Michael Schäfers Journal: J Nucl Med Date: 2005-06 Impact factor: 10.057
Authors: Thorsten Fuereder; Thomas Wanek; Pamina Pflegerl; Agnes Jaeger-Lansky; Doris Hoeflmayer; Sabine Strommer; Claudia Kuntner; Friedrich Wrba; Johannes Werzowa; Michael Hejna; Markus Müller; Oliver Langer; Volker Wacheck Journal: Clin Cancer Res Date: 2011-06-28 Impact factor: 12.531
Authors: Kan V Lu; Jeffrey P Chang; Christine A Parachoniak; Melissa M Pandika; Manish K Aghi; David Meyronet; Nadezda Isachenko; Shaun D Fouse; Joanna J Phillips; David A Cheresh; Morag Park; Gabriele Bergers Journal: Cancer Cell Date: 2012-07-10 Impact factor: 31.743
Authors: Olivier Keunen; Mikael Johansson; Anaïs Oudin; Morgane Sanzey; Siti A Abdul Rahim; Fred Fack; Frits Thorsen; Torfinn Taxt; Michal Bartos; Radovan Jirik; Hrvoje Miletic; Jian Wang; Daniel Stieber; Linda Stuhr; Ingrid Moen; Cecilie Brekke Rygh; Rolf Bjerkvig; Simone P Niclou Journal: Proc Natl Acad Sci U S A Date: 2011-02-14 Impact factor: 11.205
Authors: Kathleen M Schmainda; Melissa Prah; Jennifer Connelly; Scott D Rand; Raymond G Hoffman; Wade Mueller; Mark G Malkin Journal: Neuro Oncol Date: 2014-01-15 Impact factor: 12.300
Authors: Ta-Jen Liu; Dimpy Koul; Tiffany LaFortune; Ningyi Tiao; Rui Jun Shen; Sauveur-Michel Maira; Carlos Garcia-Echevrria; W K Alfred Yung Journal: Mol Cancer Ther Date: 2009-08-11 Impact factor: 6.261
Authors: Nicolas Graf; Zhoulei Li; Ken Herrmann; Daniel Weh; Michaela Aichler; Jolanta Slawska; Axel Walch; Christian Peschel; Markus Schwaiger; Andreas K Buck; Tobias Dechow; Ulrich Keller Journal: Onco Targets Ther Date: 2014-05-23 Impact factor: 4.147
Authors: Silvia Valtorta; Daniela Salvatore; Paolo Rainone; Sara Belloli; Gloria Bertoli; Rosa Maria Moresco Journal: Int J Mol Sci Date: 2020-08-06 Impact factor: 5.923